NO159800C - Analogifremgangsmaate til fremstilling av terapeutisk aktive 20-spiroksaner og analoge med aapnet ring e. - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk aktive 20-spiroksaner og analoge med aapnet ring e.

Info

Publication number
NO159800C
NO159800C NO841465A NO841465A NO159800C NO 159800 C NO159800 C NO 159800C NO 841465 A NO841465 A NO 841465A NO 841465 A NO841465 A NO 841465A NO 159800 C NO159800 C NO 159800C
Authority
NO
Norway
Prior art keywords
spiroxanes
analogue
preparation
therapeutically active
open ring
Prior art date
Application number
NO841465A
Other languages
English (en)
Norwegian (no)
Other versions
NO159800B (no
NO841465L (no
Inventor
Juergen Grob
Jaroslav Kalvoda
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO841465L publication Critical patent/NO841465L/no
Publication of NO159800B publication Critical patent/NO159800B/no
Publication of NO159800C publication Critical patent/NO159800C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO841465A 1983-04-13 1984-04-12 Analogifremgangsmaate til fremstilling av terapeutisk aktive 20-spiroksaner og analoge med aapnet ring e. NO159800C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (3)

Publication Number Publication Date
NO841465L NO841465L (no) 1984-10-15
NO159800B NO159800B (no) 1988-10-31
NO159800C true NO159800C (no) 1989-02-08

Family

ID=4223123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO841465A NO159800C (no) 1983-04-13 1984-04-12 Analogifremgangsmaate til fremstilling av terapeutisk aktive 20-spiroksaner og analoge med aapnet ring e.

Country Status (23)

Country Link
US (1) US4559332A (index.php)
EP (1) EP0122232B1 (index.php)
JP (1) JPS59231100A (index.php)
AR (4) AR241918A1 (index.php)
AT (1) ATE39256T1 (index.php)
AU (1) AU565017B2 (index.php)
CA (1) CA1220781A (index.php)
DD (2) DD233375A5 (index.php)
DE (2) DE3475622D1 (index.php)
DK (1) DK163988C (index.php)
ES (4) ES531517A0 (index.php)
FI (1) FI77669C (index.php)
GR (1) GR81834B (index.php)
HU (1) HU191406B (index.php)
IE (1) IE57541B1 (index.php)
IL (1) IL71504A (index.php)
LU (1) LU91072I2 (index.php)
NL (1) NL300144I1 (index.php)
NO (1) NO159800C (index.php)
NZ (1) NZ207826A (index.php)
PH (1) PH19997A (index.php)
PT (1) PT78413B (index.php)
ZA (1) ZA842710B (index.php)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
EP0526642B1 (en) * 1991-01-29 1998-04-01 Shionogi Seiyaku Kabushiki Kaisha Triterpene derivative
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
BR9609066A (pt) * 1995-06-07 1999-01-26 Searle & Co Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
WO1997021720A2 (en) * 1995-12-11 1997-06-19 G.D. Searle And Co. Processes for preparation of 7 alpha-carboxyl 9,11-epoxy steroids and intermediates useful therein and a general process for the epoxidation of olifinic double bonds
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
EP1167380A3 (en) * 1995-12-11 2004-12-08 G.D. Searle & Co. 11.alpha.-hydroxy-steroid-4,6-dien-3-one compounds and a process for their preparation
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
ZA9711038B (en) * 1996-12-11 1999-01-25 Searle & Co Spr process for preparation of 9,11-Epoxy steroids and intermediates useful therein
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
ES2293944T3 (es) * 1996-12-11 2008-04-01 G.D. Searle Llc. Procedimiento de epoxidacion.
EP1223174A3 (en) * 1996-12-11 2005-03-16 G.D. Searle & Co. Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein
CA2298453A1 (en) * 1998-05-29 1999-12-09 Kyowa Hakko Kogyo Co., Ltd. Process for producing seasoning liquors with flavor of vegetables pickled in salted rice bran paste
KR20010100986A (ko) * 1998-11-06 2001-11-14 로저 에이. 윌리암스 심장혈관 질병으로 인한 이병률 및 사망률 감소용안지오텐신 전환 효소 억제제 및 알도스테론 길항제의결합 치료방법
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
ES2200588T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinacion de inhibidores del transporte de oxido biliar ileal y de derivados de acido fibrico para indicaciones cardiovasculares.
DK1140190T3 (da) * 1998-12-23 2002-12-23 Searle Llc Kombinationer af ileumgaldesyretransport-inhibitorer og galdesyre-sekvestreringsmidler til cardiovaskulære indikatorer
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
PL348508A1 (en) 1998-12-23 2002-05-20 Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
PT1140184E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
EP1140185B1 (en) 1998-12-23 2003-06-04 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
EP1354604A1 (en) * 1998-12-23 2003-10-22 G.D. Searle LLC. Combinations for cardiovascular indications
NZ512534A (en) * 1998-12-23 2003-11-28 G Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
WO2001042272A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Eplerenone crystalline form exhibiting enhanced dissolution rate
KR100584104B1 (ko) * 1999-12-08 2006-05-30 파마시아 코포레이션 결정형 에플레레논
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
WO2001068637A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
CA2409437A1 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
DK1303306T3 (da) * 2000-07-27 2006-10-23 Pharmacia Corp Epoxysteroidaldosteronantagonist og beta-adrenerg antagonist-kombinationsterapi til behandling af kongestivt hjertesvigt
CA2419256A1 (en) * 2000-08-28 2002-03-07 Kenton N. Fedde Use of an aldosterone receptor antagonist to improve cognitive function
CN1531590A (zh) * 2000-10-30 2004-09-22 赭曲霉11α-羟化酶和氧化还原酶
CN100408099C (zh) * 2000-11-09 2008-08-06 阿斯特拉曾尼卡有限公司 含有嵌段共聚物的口服药物组合物
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6740663B2 (en) * 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
CA2469616A1 (en) 2001-12-12 2003-06-19 James W. Aiken Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
PL373032A1 (en) * 2002-03-18 2005-08-08 Pharmacia Corporation Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
CA2479259A1 (en) * 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
JP2005520856A (ja) * 2002-03-20 2005-07-14 ファルマシア コーポレーション 貯蔵時に安定なエプレレノン製剤
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
JP2005528371A (ja) * 2002-03-22 2005-09-22 ファルマシア・コーポレーション ステロイドのｃ−１７スピロラクトニゼーションおよび６，７−酸化
TW200406419A (en) * 2002-08-16 2004-05-01 Upjohn Co 5-Androsten-3 β- ol steroid intermediates and processes for their preparation
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
PL376919A1 (pl) * 2002-11-06 2006-01-09 Pharmacia & Upjohn Company Llc Sposoby wytwarzania 7-karboksy-podstawionych steroidów
TWI280133B (en) * 2002-11-07 2007-05-01 Upjohn Co Process for preparing C-7 substituted steroids
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
CN1934126A (zh) * 2004-03-22 2007-03-21 法玛西雅厄普约翰有限责任公司 9,11环氧甾族化合物的改进制备方法
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
WO2008074098A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical composition
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
ME01923B (me) 2009-05-28 2015-05-20 Novartis Ag Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
UY32660A (es) 2009-05-28 2010-12-31 Novartis Ag Derivados aminobutricos sustituidos como inhibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011097571A2 (en) * 2010-02-08 2011-08-11 Prairie Pharmaceuticals, Llc Methods for the use of progestogen as a glucocorticoid sensitizer
JP6148175B2 (ja) 2010-05-10 2017-06-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 網膜中および／または網膜下における液体貯留の処置のための方法および組成物
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
LT2956464T (lt) 2013-02-14 2018-07-10 Novartis Ag Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
EP3009443B1 (en) 2014-10-17 2018-09-12 INDUSTRIALE CHIMICA S.r.l. Process for the preparation of 7alfa-(methoxycarbonyl)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactone, a useful intermediate for the synthesis of molecules with pharmacological activity
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
ES2973248T3 (es) 2016-07-26 2024-06-19 Inst Nat Sante Rech Med Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
ES8705459A1 (es) 1987-05-01
ES544769A0 (es) 1987-05-01
US4559332A (en) 1985-12-17
FI77669B (fi) 1988-12-30
EP0122232A1 (de) 1984-10-17
AR241918A1 (es) 1993-01-29
ZA842710B (en) 1984-11-28
EP0122232B1 (de) 1988-12-14
IE840906L (en) 1984-10-13
NL300144I2 (nl) 2004-06-01
DD233375A5 (de) 1986-02-26
IL71504A0 (en) 1984-07-31
ES544770A0 (es) 1987-05-01
DE122004000012I1 (de) 2012-05-16
AU565017B2 (en) 1987-09-03
DK163988B (da) 1992-04-27
IL71504A (en) 1987-07-31
FI841400L (fi) 1984-10-14
CA1220781A (en) 1987-04-21
AR242223A1 (es) 1993-03-31
DE122004000012I2 (de) 2006-06-08
DK163988C (da) 1992-09-21
DD251144A5 (de) 1987-11-04
AR242222A1 (es) 1993-03-31
NZ207826A (en) 1986-07-11
FI841400A0 (fi) 1984-04-09
JPH0212479B2 (index.php) 1990-03-20
DK189484A (da) 1984-10-14
GR81834B (index.php) 1984-12-12
ES8705461A1 (es) 1987-05-01
ES8602846A1 (es) 1985-12-01
PH19997A (en) 1986-08-28
IE57541B1 (en) 1992-10-07
NO159800B (no) 1988-10-31
ES544768A0 (es) 1987-05-01
NL300144I1 (nl) 2004-06-01
AR242221A1 (es) 1993-03-31
ATE39256T1 (de) 1988-12-15
PT78413B (en) 1986-08-22
AU2685384A (en) 1984-10-18
ES531517A0 (es) 1985-12-01
DE3475622D1 (en) 1989-01-19
FI77669C (fi) 1989-04-10
PT78413A (en) 1984-05-01
JPS59231100A (ja) 1984-12-25
HU191406B (en) 1987-02-27
ES8705460A1 (es) 1987-05-01
LU91072I2 (fr) 2004-04-07
NO841465L (no) 1984-10-15
DK189484D0 (da) 1984-04-12

Similar Documents

Publication Publication Date Title
NO159800C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 20-spiroksaner og analoge med aapnet ring e.
NO159016C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenetanolaminderivater.
NO841703L (no) Fremgangsmaate til fremstilling av n-alkylerte dipeptider og deres estere.
NO157738C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzoksazinoner og benzoksazolinoner.
NO161317C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive oksikamer.
NO154492C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme forbindelser.
NO871028D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazol- og oksazol-derivater.
NO158460C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO158417C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive urinstoffer og tiourinstoffer.
NO162860C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzo-(pyrano og tiopyrano)-pyridiner.
NO163775C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoindolinyl-alkyl-piperaziner.
NO159929C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive n-substituerte 2-pyridylindoler.
NO167808C (no) Fremgangsmaate til fremstilling av n-alkylerte dipeptider og deres estere.
NO851452L (no) Fremgangsmaate og cellelinje for fremstilling av plasminogene aktivatorer.
NO163570C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive acylaminomitosaner.
NO165493C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolindioner og pyridopyrimidindioner.
NO159924C (no) Fremgangsmaate for fremstilling av sement og innretning for utfoerelse av fremgangsmaaten.
NO884324D0 (no) Fremgangsmaate til fremstilling av reninhemmende peptider og deres anvendelse.
NO802277L (no) Fremgangsmaate til fremstilling av terapeutisk aktive 25-halocholest-5-en-3beta,22-dioler og estere derav
NO881713D0 (no) Fremgangsmaate for fremstilling av di-t-butylfenyl-alkyl og benzylethere.
NO166726C (no) Fremgangsmaate for fremstilling av arylglycidyletere og 3-substituerte 1-alkylamino-2-propanoler.
NO882335D0 (no) Fremgangsmaate for fremstilling av 5-(omega-ammonio-acyloksy-metylen)-tetrahydrofuraner og -tetrahydrotiofener.
NO159183C (no) Fremgangsmaate for fremstilling av lenser og liknende.
NO162964C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrazolopyridinderivater.
NO872199D0 (no) Analogifremgangsmaate for fremstilling av alkoxyalkyl- og alkylmercaptoalkylsubstituerte benzofuroisokinoliner.

Legal Events

Date Code Title Description
MK1K Patent expired